Passionate about Progress
We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with difficult to treat chronic cough conditions by targeting the central and peripheral nervous systems.
Our phase 2a RIVER trial in patients with refractory chronic cough (RCC) has been initiated, and we expect topline data in the second half of 2024. We previously announced positive results from our phase 2a CANAL trial in IPF chronic cough and we anticipate activating a phase 2b dose-ranging trial as well as a phase 1b respiratory physiology trial in IPF patients.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT and we are proud to be part of its vibrant life-science community.
“At Trevi Therapeutics, we are dedicated to the exploration and development of Haduvio for patients suffering from serious neurologically mediated chronic cough conditions where there are no approved treatment options. I am proud of the team that we have developed and their passion for improving patients’ lives.”
– Jennifer Good, Co-Founder, President & CEO